At a glance
- Originator Sankyo
- Class Antihyperlipidaemics
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 12 Jul 1999 No-Development-Reported for Hypercholesterolaemia in Japan (Unknown route)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Hypercholesterolaemia in Japan (Unknown route)